Company news

Precision BioSciences, Inc. news in 2024

Precision BioSciences, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

December 17, 2024

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

November 14, 2024

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

November 3, 2024

Precision BioSciences to Report Third Quarter Results on November 4, 2024

October 28, 2024

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

October 27, 2024

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

October 23, 2024

Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B

September 29, 2024

Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution

September 11, 2024

Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal

September 2, 2024

Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis

August 8, 2024

Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

July 31, 2024

Precision BioSciences Announces its Addition to the Russell Microcap® Index

June 30, 2024

Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025

June 26, 2024

Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness

June 19, 2024

Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 12, 2024

Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement

May 7, 2024

Precision BioSciences to Report First Quarter Results on May 13, 2024

May 6, 2024

Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency

May 6, 2024

Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024

April 30, 2024

Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics

April 15, 2024

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

March 26, 2024

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024

March 19, 2024

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency

March 5, 2024

Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants

February 29, 2024

Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants

February 28, 2024

Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences

February 19, 2024

Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness

February 13, 2024

Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations

February 12, 2024

Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases

February 11, 2024

Precision BioSciences to Effect a Reverse Stock Split

February 8, 2024

Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases

January 8, 2024

Decks in 2024